Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Core Points - Cytokinetics held a conference call to discuss the FDA approval of MYQORZO [1] Group 1 - The conference call was led by Diane Weiser, the Senior Vice President of Corporate Affairs at Cytokinetics [1]